Zhejiang Ausun Pharmaceutical Co., Ltd. was established in April 2010 and was listed on Shanghai Stock Exchange on May 9, 2017 with stock code 603229. The company is located in the coastal park of chemical API base in toumengang Economic Development Zone, Zhejiang Province. It is the first pharmaceutical enterprise with Academician workstation in Taizhou medical and chemical enterprises. It is also a high-tech enterprise. At present, the company has built excellent platforms such as Zhejiang Provincial Research Institute, provincial enterprise technology center, provincial academician expert workstation and provincial postdoctoral workstation. There are nearly 800 employees and a research, development and analysis team composed of more than 200 doctors and masters. The company is mainly engaged in the R & D, production and sales of pharmaceutical preparations, characteristic APIs and key pharmaceutical intermediates, as well as providing customized processing and R & D business for customers; The products are mainly exported to Europe, the United States, Japan, South Korea and other countries and regions. From January to June 2020, the company's operating revenue increased by 62.38% year-on-year, and its net profit increased by 69.46% year-on-year. The company's products are mainly divided into eight categories: liver disease, respiratory system, cardio cerebrovascular, high-end fluorine products, prostaglandins, antibiotics, gout and anti-tumor. The products developed have many chiral structures, difficult research and development, high technical barriers and unique production process. The company attaches great importance to technological innovation and research and development. In recent three years, R & D investment accounted for more than 12% of operating revenue (including 15.51% in 2019). Focusing on the health industry, the company always adheres to the core concept of "quality + innovation", takes "serving health and creating the future" as the enterprise purpose, takes "talent and win-win" as the guiding ideology of development in accordance with the requirements of the 14th five year plan of China's pharmaceutical industry and the national innovation and development strategy, Build a world-class R & D and innovation system with the ability to create new drugs and generic pharmaceutical technology, constantly expand the coverage of sales network, actively explore high-end standardized markets in the United States, Japan and Europe, and strive to become a characteristic pharmaceutical enterprise with global competitiveness in the future.